Intra-Cellular Therapies Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Intra-Cellular Therapies ha un patrimonio netto totale di $1.1B e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $1.3B e $179.6M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$1.01b
Patrimonio netto	US$1.14b
Totale passività	US$179.62m
Totale attività	US$1.32b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $1.3B ) di 23I superano le sue passività a breve termine ( $166.1M ).

Passività a lungo termine: Le attività a breve termine di 23I ( $1.3B ) superano le sue passività a lungo termine ( $13.5M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 23I è esente da debiti.

Riduzione del debito: 23I non aveva debiti 5 anni fa.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 23I ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: Dati insufficienti per determinare se 23I ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.

Intra-Cellular Therapies Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

Intra-Cellular Therapies, Inc. Raises Financial Guidance for the Full Year 2024

Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.25 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.45 loss in 2Q 2023)

Intra-Cellular Therapies, Inc. Raises Sales Guidance for 2024

Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 2000 Dynamic Index

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.46 loss in 1Q 2023)

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 14, 2024

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

New minor risk - Shareholder dilution

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer

Full year 2023 earnings released: US$1.46 loss per share (vs US$2.73 loss in FY 2022)

New minor risk - Shareholder dilution

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024

Forecast to breakeven in 2025

EVP & Chief Commercial Officer recently sold €801k worth of stock

Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.57 loss in 3Q 2022)

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.45 loss per share (vs US$0.92 loss in 2Q 2022)

Forecast to breakeven in 2025

Intra-Cellular Therapies, Inc. Announces CAPLYTA Data Presentations At the American Society of Clinical Psychopharmacology Annual Meeting

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.46 loss per share (vs US$0.78 loss in 1Q 2022)

Full year 2022 earnings released: US$2.73 loss per share (vs US$3.50 loss in FY 2021)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Independent Director recently sold €240k worth of stock

Independent Director recently sold €523k worth of stock

Independent Director recently sold €523k worth of stock

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$0.94 loss in 3Q 2021)

Independent Director recently sold €573k worth of stock

Second quarter 2022 earnings released: US$0.92 loss per share (vs US$0.85 loss in 2Q 2021)

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.65 loss in 1Q 2021)

Intra-Cellular Therapies, Inc. Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 09, 2022

Independent Director recently sold €736k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Forecast to breakeven in 2024

Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$0.79 loss in 3Q 2020)

Intra-Cellular Therapies, Inc. Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

Second quarter 2021 earnings released: US$0.85 loss per share (vs US$0.96 loss in 2Q 2020)

Forecast to breakeven in 2023

High number of new directors

Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: US$0.65 loss per share (vs US$0.73 loss in 1Q 2020)

Intra-Cellular Therapies Announces FDA Acceptance of Caplyta (Lumateperone) SNDAs for the Treatment of Bipolar Depression

Revenue beats expectations

Intra-Cellular Therapies Announces Expansion of Pipeline with the Introduction of New Molecular Entity, ITI-1284

Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression

New 90-day high: €32.85

New 90-day high: €29.02

Intra-Cellular Therapies, Inc. Announces the Publication of Results from the CAPLYTA Clinical Trial (ITI-007-303)

New 90-day high: €27.41

Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder

New 90-day high: €23.82

Senior VP of Finance recently sold €174k worth of stock

Revenue beats expectations

Intra-Cellular Therapies, Inc. Announces Executive Changes

Intra-Cellular Therapies, Inc. Announces Executive Changes

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $350.00001 million.

New 90-day low - €15.16

New 90-day low - €16.08

First half earnings released

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane